Legal and Medical Cannabis Market Expected to Show Strong Growth

NEW YORK, September 26, 2017 /PRNewswire/ --

According to a report by Hexa Research the U.S. medical cannabis market was valued at USD 5.44 billion in 2016, and is expected to be valued at USD 19.48 billion by 2024. The legal cannabis market is expected to be driven by its numerous medical benefits particularly in for fields of oncology, chronic pain and diabetes. Chronic pain was the largest segment owing to the presence of a large number of patients last year. In 2016, Washington D.C. together with other 28 states legitimated the use cannabis for medical purpose. Favorable regulatory environment across numerous states, including the largest markets, California and Colorado, is expected to contribute to the strong projected growth. Global Payout, Inc. (OTC: GOHE), Cara Therapeutics Inc. (NASDAQ: CARA), American Cannabis Company, Inc. (OTC: AMMJ), Cannabis Science, Inc. (OTC: CBIS), OWC Pharmaceutical Research Corp. (OTC: OWCP)

"Significant changes are already underway in California for medical cannabis and adult use laws, which we see will have major implications for the cannabis industry, including ecommerce and delivery services in the state," said Giadha Aguirre de Carcer, New Frontier Data CEO. "As the largest state in the country - and the largest potential market for cannabis products - the implications for the growth of the industry because of California's adult use market cannot be overstated."

Global Payout, Inc. (OTC: GOHE) announced on September 18th that, "executive management members of its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") successfully represented the Company this past week at the 4th annual Cannabis World Congress & Business Exposition held in Los Angeles, CA.
The expo has become one of the most prominent cannabis-related conferences held in the U.S. and brings together exhibitors who feature the latest technologies, solutions, and resources for businesses operating within the cannabis industry. While in attendance at the expo, members of the Company's executive management team, including Vanessa Luna, COO, strategically utilized it as an opportunity to network with other key figures and business owners throughout the industry to effectively promote and represent the MTRAC brand."

"Representation at events such as this present such a unique and powerful opportunity to grow our presence and establish new partnerships within an industry that is incredibly tight-knit and yet growing at an unprecedented rate," said MTRAC COO, Vanessa Luna. "I am encouraged by the many different connections we established during this expo, and I am optimistic about the likelihood of a decent number of them possibly materializing into new partnerships for our company at some point in the near future," Ms. Luna further remarked.

Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Cara's most advanced CB compound, CR701, is in preclinical development. CR701 has been evaluated in a rodent model of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions. Dr. Joseph Stauff, CMO of Cara Therapeutics, said, "Cannabinoid Receptor Agonists like CR701 have the potential to provide improved pain relief for patients suffering from neuropathic pain." 

American Cannabis Company, Inc. (OTCQB: AMMJ), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, announced on September 21st, that it has signed an exclusive distribution agreement with Earth Alive, a leading Canadian clean-tech company that develops and manufactures state-of-the-art microbial technology-based products. This agreement allows for the commercialization of Earth Alive's premiere cannabis microbial inoculant product, called Dr. Marijane. Dr. Marijane is a certified organic root probiotic that promotes increased vegetative growth, improves the bioavailability of fertilizer programs, and sustains healthy development and structuring of plant roots.

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the full publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal, Frontiers in Oncology, released on September 19th. "The laboratory work from CBIS' collaborations are moving apace and more results are to be reported soon," stated Mr. Raymond C. Dabney, Cannabis Science Inc., President & CEO, Co-Founder. Currently, early results show that using smart drug-delivery systems to deliver cannabinoids directly to tumor cells leads to increased tumor cell kill in animal models of lung and pancreatic cancer, which are some of the deadliest cancers.

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. On June 27th, OWC Pharmaceutical Research announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd., has filed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. This new patent application follows the previously filed 'provisional' patent application. The added protection that this patent application provides for OWC's intellectual property will enable the Company to accelerate its ongoing discussions and negotiations regarding scientific, medical and commercial collaboration. 

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand seven hundred fifty dollars for financial news dissemination and pr services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.

For further information: 

Media Contact:
[email protected]
Phone- +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com